The effect of anticancer drugs and toxic compounds on cultures of human leukemic cells was evaluated by an enzyme-linked immunosorbent assay (Apoptosis ELISA) that uses a monoclonal antibody against single-stranded DNA to quantitate the apoptotic cells. The concentrations of 13 anticancer drugs, which increased Apoptosis ELISA absorbance, were close to the cytotoxic concentrations determined by the long-term cell survival assay. Short-term tetrazolium-based microculture tetrazolium (MTT) assay was significantly less sensitive than the Apoptosis ELISA and the cell survival assay for all anticancer drugs. For 6 drugs, cytotoxic concentrations measured by the MTT assay were at least 1 log higher than the concentrations inducing apoptosis. Importantly, in contrast to the anticancer drugs, 14 toxic chemicals did not increase the Apoptosis ELISA absorbance at cytotoxic concentrations. The difference in apoptosis induction by the anticancer drugs and the toxic chemicals was especially large in cultures treated with drug concentrations 2-fold higher than the IC 50 dose. Although all of the anticancer drugs tested induced intense ELISA reaction (mean absorbance 2.0), all toxic chemicals tested did not induce apoptosis. The Apoptosis ELISA assay could have useful applications in drug development as it can distinguish between clinically useful anticancer drugs and toxic compounds, has sensitivity similar to that of the long-term cell survival assay, and provides insight into the mechanism of drug cytotoxicity by differentiating between compounds killing cells by apoptosis and necrosis. (Journal of Biomolecular Screening 2003:185-190) 
INTRODUCTION
T HE RATIONALE FOR THE USE of apoptosis as a marker for cytotoxicity in drug screening is based on the observation that all clinically active anticancer drugs induce apoptosis in malignant cells. [1] [2] [3] The correlation between drug-induced apoptosis and tumor response to treatment in vivo also supports the use of apoptosis assays in drug screening. [4] [5] [6] Quantitative analysis of apoptosis demonstrated that, at least in leukemic cells in culture, apoptotic death accounts for all or most of the cell killing by the anticancer drugs. 7 Importantly, induction of apoptosis results in complete eradication of established tumors in vivo without any toxic effects on normal tissues. 8 The advantage of using apoptosis as a marker of drug effect is based on the fact that apoptosis is a direct reflection of cell death, whereas other short-term tests (e.g., tetrazolium, thymidine, ATP) detect metabolic disturbances, which may not result in cytotoxicity. The Apoptosis ELISA could have useful application in drug development as a major goal of in vitro screening is rapid detection of drug effects on cell viability without reliance on the labor-intensive long-term cell survival assays such as the clonogenic assay. Apoptosis assays also provide insight into the mechanism of drug cytotoxicity by differentiating between apoptosis and necrosis.
To determine the utility of the Apoptosis ELISA in drug development, we compared the Apoptosis ELISA with the short-term tetrazolium-based microculture tetrazolium (MTT) assay and the long-term cell survival assay. Two types of compounds were tested by these assays: the clinically useful anticancer drugs with different mechanisms of actions and the reference toxic compounds without antitumor activity. 9, 10 First, the Apoptosis ELISA was compared with the cell survival assay to determine whether the apoptosis assay can detect cell killing with a sensitivity similar to that of the assay measuring the loss of long-term proliferative potential. Second, we evaluated the ability of the Apoptosis ELISA to distinguish between compounds with antitumor activity and toxic chemicals as this discrimination could be useful for the selection of leads during screening of unknown compounds.
The Apoptosis ELISA used in this study is based on the selective DNA denaturation in condensed chromatin of the apoptotic cells by formamide and the staining of single-stranded DNA (ssDNA) by monoclonal antibodies (MAb) highly specific to DNA in the single-stranded conformation. These antibodies specifically detect the apoptotic cells but do not react with the necrotic cells or the nonapoptotic cells with drug-induced DNA damage. Sensitive detection of the apoptotic cells with anti-ssDNA MAb was observed in cell cultures and in primary human tumors. [11] [12] [13] The specificity of the assay is based on the MAb reaction with condensed chromatin in early and late apoptotic cells. [11] [12] [13] Because chromatin condensation is the most universal and specific apoptotic marker, which indicates irreversible commitment to apoptosis, this assay provides precise assessment of cell death. In contrast, assays based on the measurement of caspases could be less sensitive markers of the cell death, as tumor cells can survive the activation of the caspases and some drugs induce caspase-independent apoptosis. 14 The widely used TUNEL assay may not be useful for apoptosisbased drug screening as it is not specific for apoptosis and reacts also with the necrotic cells. [11] [12] [13] Adaptation of the anti-ssDNA MAb-based apoptosis assay for use in 96-well plates made it possible to use it in routine drug screening. 15 The sensitivity of the Apoptosis ELISA in the multiwell plates was characterized by the detection of as little as 500 apoptotic cells and by a linear relation between absorbance and cell number. The Apoptosis ELISA provides a rapid and convenient method for the evaluation of drug-induced apoptotic response as all the steps needed for the procedure, including culture growth, drug treatment, and staining, are performed in the same 96-well plate. The one-step immunostaining by a mixture of primary and secondary antibody eliminates the need for incubation and rinsing steps and makes the procedure amiable for automation.
The specific and sensitive detection of the apoptotic cells in microplates is an important advantage of our Apoptosis ELISA because other assays cannot be used for the specific detection of the apoptosis in microplates. For example, binding of annexin V to the cell surface specifically detects the apoptotic cells, provided the annexin-positive necrotic cells with damaged membrane are identified after propidium iodide staining by flow cytometry. However, in microplates, the annexin V assay cannot distinguish between binding of annexin V to the apoptotic and the necrotic cells when total binding in the well is measured. Because compounds, which induce apoptosis as the primary mechanism for cell killing, may include agents with possible anticancer activity, the application of specific apoptosis assays in routine drug screening may provide useful leads.
The sensitivity of the cytotoxicity assays also could be critical for the detection of leads in initial drug screening. An important conclusion of the National Cancer Institute (NCI) preclinical drugscreening program is that compounds with antiproliferative effect at 1 µM or less in vitro have a higher probability of being active in responsive tumors. 16 These data strongly indicate that drug-screening assays with maximal in vitro sensitivity could be most useful for the prediction of in vivo antitumor activity. Indeed, we have demonstrated that the Apoptosis ELISA provides a clear distinction between the anticancer drugs and the toxic chemicals, based on the fact that among compounds tested in this study, only clinically active antitumor agents induced apoptosis at concentrations of 1 µM or below in leukemic cell cultures.
MATERIALS AND METHODS

Materials
Cell culture reagents (medium, FBS, and Glutamax) were purchased from Gibco (Grand Island, NY). Drugs and chemicals were obtained from Sigma (St. Louis, MO). The mixture of primary anti-ssDNA MAb F7-26 with peroxidase-conjugated antimouse IgM for one-step ELISA immunostaining was supplied by Apostain (Miami, FL). The generation and binding specificity of MAb F7-26 were described previously. 11, 17 Cell culture Suspension cultures of human T cell leukemia cell line MOLT-4 were grown in RPMI 1640 medium supplemented with 7.5% FBS, 2 mM Glutamax I, and 10 -5 M 2-mercaptoethanol (complete medium). Aliquots of 10 4 cells in 200 µl of complete medium from log phase cultures (5-6 × 10 5 cells/ml) were seeded in each well of the 96-well flat-bottomed culture-treated Costar plates. Plates were incubated at 37°C in a humidified atmosphere of 5% CO 2 for 24 h before treatment. Then, 50 µl of drug solutions in complete medium containing 5× of the final drug concentration was added to each well. Control wells received 50 µl of complete medium. Six wells were used for each drug concentration, and cultures were incubated for 24 to 48 h.
Enzyme-linked immunosorbent assay
Apoptosis ELISA, based on the use of the antibody to ssDNA, was performed as described earlier. 15 Plates incubated with drugs for 24 h were centrifuged, and culture medium was removed by vacuum using immuno washer (Nunc, Naperville, IL) and replaced with 200 µl of 80% methanol in phosphate-buffered saline (PBS). After 30 min incubation at room temperature, plates were centrifuged, fixative was removed, and plates were dried by incubation at room temperature for 2 to 24 h or by floating in a water bath for 20 min at 37°C. Wells with dried cells were filled with 50 µl of formamide, and plates were incubated for 20 min in an oven preheated to 70 to 75°C to denature DNA of the apoptotic cells. Single-stranded DNA was then stained using the following steps: (a) blocking of nonspecific binding with 3% nonfat dry milk, (b) staining with anti-ssDNA MAb F7-26 mixed with peroxidaseconjugated antimouse IgM, (c) washing with PBS, and (d) incuba-tion with peroxidase substrate and measurement of mean absorbance of 6 wells at 405 nm in a plate reader (MRX Revelation plate reader, Dynatech, Chantilly, VA). The data presented are a mean of 3 to 5 independent experiments with ± standard error.
MTT assay
This assay detects reduction of MTT by mitochondrial dehydrogenase of viable cells to a blue formazan product. 18 Following incubation with drugs for 48 h, 50 µl of 2 mg/ml MTT was added to each well. After mixing with a multipipetor, plates were incubated at 37°C for 4 h. Centrifugation was followed by replacement of the medium with 150 µl of DMSO. Absorbance in control and drug-treated wells was measured in a plate reader at 550 nm.
Cell survival assay
Effects of drugs on cell viability were determined by regrowth of drug-treated cells in drug-free medium. Cells from plates treated with drugs for 24 h were collected, and 10 4 cells were seeded into 6-well plates in 5 ml of complete medium. Plates were incubated for 6 days, and cells were counted in a hemacytometer. Percentage of growth inhibition was calculated as a ratio of cell numbers in cultures seeded with drug-treated and control cells. After 6 days of incubation, the cell number in control wells increased from 10 4 to 1 to 2 × 10 6 , corresponding to approximately 6 to 7 cell doublings. This assay measures the effect of drugs on the long-term cell proliferation similarly to colony formation assays (usually 5-6 cycles of cell divisions).
RESULTS
Effects of anticancer drugs on human leukemic MOLT-4 cells
were evaluated by Apoptosis ELISA, cell survival, and MTT assays. Dose-response curves were developed from incubation of cells with a range of concentrations of the 13 drugs tested. Typical results for etoposide (topoisomerase II inhibitor) are presented in Figures 1 through 3, and data for all drugs tested are summarized in Table 1 . Apoptosis as measured by absorbance in the Apoptosis ELISA increased linearly in the concentration range 0.05 to 0.25 µM of etoposide ( Fig. 1) . Treatment with 0.115 µM etoposide increased absorbance 2-fold relative to the control cultures (optical density 1.0). Drug concentrations, which doubled absorbance in the Apoptosis ELISA, were used to characterize apoptosis-inducing activity of the drugs tested ( Table 1) .
The cell survival curve for etoposide was similar to the apoptosis dose-response curve with near linear response in the same dose range as the Apoptosis ELISA (Fig. 2) . Drug concentration decreasing cell survival by 50% (IC 50 ) was close to the concentration, which doubled Apoptosis ELISA absorbance (Table 1 ). In contrast, etoposide concentration, which produced 50% inhibition in the MTT assay, was nearly 10-fold higher than the effective dose determined from the apoptosis and the cell survival curves (Fig. 3 , Table 1 ). Similarly, the concentrations of other 12 anticancer drugs inducing apoptosis and decreasing long-term cell survival were very close (Table 1 ).
For all drugs tested, the MTT assay was significantly less sensitive than the Apoptosis ELISA and the cell survival assays. The difference was especially large for etoposide, alkylating agents, and microtubule inhibitors. For example, MTT IC 50 was 10-fold or more higher than apoptosis and cell survival effective concentrations for etoposide, L-PAM, nitrogen mustard, taxol, vinblastine, and vincristine. The low sensitivity of the MTT assay did not result from an inability to detect small changes in cell numbers as dem- onstrated by near linear relation between MTT absorbance and the number of control cells in the range 2 to 50 × 10 3 cells/well (Fig. 4) . The duration of drug treatments was 1 day for the Apoptosis ELISA and the cell survival assays but 2 days for the MTT assay. One day of incubation for the Apoptosis ELISA was optimal as with continued incubation, the apoptotic cells in MOLT-4 cultures degenerated by secondary necrosis. Similar length of drug exposure was used for the Apoptosis ELISA and the cell survival assays as our goal was to compare sensitivity of these two methods. For the MTT assay, we used 2 days of drug incubation, as it is the stan-dard procedure used for monitoring drug effect by this assay. Despite the longer drug incubation time, the MTT assay was much less sensitive than the two other assays used. Importantly, Apoptosis ELISA after short-term drug exposure had sensitivity similar to that of the long-term cell survival assay.
Because a major goal of the in vitro drug screening is to identify drugs that may have antitumor activity in vivo, we compared the induction of apoptosis by toxic chemicals without known anticancer activity with the effect of known anticancer drugs described in the previous section. We were interested in finding if Apoptosis ELISA could be helpful in discriminating between these two types of compounds. The toxic chemicals used in this study were selected from the list of reference compounds used for in vitro toxicity screens. 9,10 These compounds were tested by the cell survival assay and the Apoptosis ELISA.
The toxic chemicals listed in Table 2 had measurable cytotoxic activity in the dose range tested (0.1-50 µM), and for these compounds, the induction of apoptosis was studied at the IC 50 dose. Data presented in Table 2 show that in contrast to the anticancer drugs, toxic chemicals do not induce apoptosis at IC 50 concentrations. To test further the ability of the Apoptosis ELISA to distinguish between anticancer drugs and toxic chemicals, we compared induction of apoptosis at equitoxic concentrations of 2× IC 50 . The results shown in Figures 5 and 6 demonstrate that at these concentrations, all anticancer drugs induced intense Apoptosis ELISA signal, whereas toxic chemicals did not produce significant apoptosis response in the leukemic cell cultures.
DISCUSSION
The high sensitivity of the Apoptosis ELISA and its ability to distinguish between anticancer drugs and toxic compounds without antitumor activity demonstrate that the Apoptosis ELISA could have useful application for the screening of drugs with anticancer activity. Indeed, sensitivity of our short-term Apoptosis ELISA was similar to that of the long-term cell survival assay and significantly better than that of the short-term MTT assay. The Apoptosis ELISA detected drug effects at low doses that could not be detected by the MTT assay and in a significantly shorter time than the cell survival assay. Most important, Apoptosis ELISA distinguished clinically useful anticancer drugs from toxic compounds without known antitumor activity. This discrimination was based on the fact that in cell cultures used in this study, only the anticancer drugs induced apoptosis at the cytotoxic concentrations.
In our leukemic cell cultures, the concentration of the anticancer drugs inducing significant Apoptosis ELISA absorbance was lower than those producing 50% inhibition in the short-term MTT assay. The difference in effective concentrations between the two assays was 1 log or more for 6 of the 13 drugs tested. The effective drug concentrations detected by the apoptosis ELISA were true reflections of drug activity as they were similar to the results obtained by measuring a decrease in long-term proliferative potential.
The conclusions drawn by the NCI screening program about the critical significance of the effective in vitro dose for the selection of promising compounds 16 should have a major bearing on the strategy for drug screening. Because compounds active in vitro at low concentrations had a high probability of affecting tumor growth in vivo, it is important to use the most sensitive assay available for drug screening. Underestimation of the cytotoxic effects by the MTT assay (as shown in the present report) or by other short-term assays 19 could have a negative impact on drug development. In this regard, it is important to note that all anticancer drugs analyzed in the present study were effective at 1 µM or lower con-centrations when tested by the Apoptosis ELISA, whereas the MTT assay missed 6 of 13 drugs with known clinical antitumor activity if the 1 µM concentration threshold was selected.
As shown in the present study, all antitumor drugs tested in the MOLT-4 cultures induced intense apoptosis, whereas all toxic agents had no apoptotic activity at concentrations with a similar cytotoxic activity. Thus, for the agents examined in this study, the Apoptosis ELISA screen clearly discriminates between clinically active anticancer drugs and toxic compounds without known antitumor activity. Interestingly, the cell survival assay lacked this discrimination, as 2 of the toxic compounds tested in this assay had IC 50 of 1 µM or lower.
MOLT-4 cells used in the present study are highly sensitive to the induction of apoptosis by chemotherapeutic agents and ionizing radiation. 7, 20 Hematological origin and expression of the wildtype p53 in this cell line could be responsible for the intense apoptotic response in these cells. 21, 22 There is a general consensus that in contrast to malignant cells of hematological origin, apoptosis is not a predominant mechanism of cell death in epithelial cancer cells treated with common anticancer drugs. [23] [24] [25] 
FIG. 5. Induction of apoptosis in MOLT-4 cell by anticancer drugs.
Cultures were treated for 24 h with drug concentrations equal to 2-fold of cell survival IC 50 , as presented in Table 1 .
FIG. 6. Induction of apoptosis in MOLT-4 cell by toxic chemicals.
Cultures were treated for 24 h with concentrations of compounds equal to 2-fold of cell survival IC 50 , as presented in Table 2 .
It is tempting to speculate that curability of the hematological cancers by common anticancer drugs is associated with the intense apoptotic response. 3 It could be suggested then that the selection of agents producing such response in epithelial cancers may increase their curability. Indeed, xenografts of human gliomas were cured by specific inducers of apoptosis. 8 The ability of the Apoptosis ELISA to select agents that have apoptosis as the main mechanism of cell killing in nonhematological cancers was demonstrated previously by the evaluation of staurosporine effects on breast cancer cells. 15 The fact that cytotoxic effects of staurosporine in breast cancer cells could be accounted for by apoptotic cell death indicates that epithelial cancers may have the potential for intense apoptotic response, and it is a question of finding the proper drugs to elicit this response.
In conclusion, Apoptosis ELISA may have useful applications in drug development and screening as this assay can distinguish between clinically useful anticancer drugs and toxic compounds without known antitumor activity. Sensitivity of the Apoptosis ELISA is similar to that of other assays that detect loss of longterm proliferative potential and significantly higher than that of the short-term metabolic MTT assay.
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